Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22503

Shown on this page

Current sort

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

MD Anderson Cancer Center

Live official records

Open in full search

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Interventions: JNJ-79635322; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Duarte, California • Irvine, California • San Francisco, California + 5 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322, Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 35 more

Conditions: Primary Breast Augmentation, Primary Breast Reconstruction, Revision Breast Augmentation, Revision Breast Reconstruction
Interventions: MemoryShape® Breast Implants, MemoryGel® Breast Implants, Other Aesthetic Surgery; Device · Procedure
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3,603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 78
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 64 more

Conditions: Data Collection, Sickle Cell Disease
Interventions: data collection; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 39 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 455
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more

Conditions: Depression, Anxiety, Cancer
Interventions: Psilocybin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dermatitis, Atopic
Interventions: JNJ-95597528, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Fountain Valley, California • Los Angeles, California • Santa Ana, California + 9 more

Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions: zagociguat 15mg; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Clinical trials in Houston, Texas

Filter and sort this location

Institutions in Houston

Live official records

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Memory Gel and Shape Combined Cohort

Data Collection For Patients With Sickle Cell Disease

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)